Next Generation Postprocessing Software Receives FDA Clearance
By MedImaging International staff writers Posted on 05 Jul 2011 |
A new magnetic resonance (MR) advanced visualization platform has been designed to help clinicians process and analyze images anytime and anywhere.
GE Healthcare (Chalfont St. Giles, UK) announced US Food and Drug Administration (FDA) clearance of Ready View software. Part of the Dexus workflow, Ready View is accessible through any personal computer (PC), picture archiving and communication system (PACS), or radiology information system (RIS) workstation, allowing access to process and analyze images in any office, meeting room or even at home.
The Ready View advanced visualization platform provides a combination of protocols, applications, and advanced tools that enable a fast, easy, and quantified analysis. In addition to standard and advanced protocols, such as four-dimensional (4D) review and image averaging, Ready View offers fast and accurate multiparametric protocols, such as brain oncology, knee, and liver. Multiparametric protocols offer a new, simple, and intuitive workflow to process all functional data from a single screen without having to leave a reading station.
"MR is moving to quantitative analysis to improve lesion detection, characterization, or monitoring," said Jim Davis, general manager, global MR business GE Healthcare. "The Ready View platform is the first step in bringing clinicians a fast and easy way to process and analyze MR data anytime and anywhere. With Ready View, clinicians can automatically segment an abnormality, convert into a 3D volume, then quickly see, and export the curve and associated statistics to the segmented area. "
Combining Ready View's accessibility with its many productivity tools such as autoprocessing, save state, one-click motion correction, and real time thresholding and segmentation, the software will not only help streamline image processing and analysis but help clinicians provide an effective diagnosis.
Related Links:
GE Healthcare
GE Healthcare (Chalfont St. Giles, UK) announced US Food and Drug Administration (FDA) clearance of Ready View software. Part of the Dexus workflow, Ready View is accessible through any personal computer (PC), picture archiving and communication system (PACS), or radiology information system (RIS) workstation, allowing access to process and analyze images in any office, meeting room or even at home.
The Ready View advanced visualization platform provides a combination of protocols, applications, and advanced tools that enable a fast, easy, and quantified analysis. In addition to standard and advanced protocols, such as four-dimensional (4D) review and image averaging, Ready View offers fast and accurate multiparametric protocols, such as brain oncology, knee, and liver. Multiparametric protocols offer a new, simple, and intuitive workflow to process all functional data from a single screen without having to leave a reading station.
"MR is moving to quantitative analysis to improve lesion detection, characterization, or monitoring," said Jim Davis, general manager, global MR business GE Healthcare. "The Ready View platform is the first step in bringing clinicians a fast and easy way to process and analyze MR data anytime and anywhere. With Ready View, clinicians can automatically segment an abnormality, convert into a 3D volume, then quickly see, and export the curve and associated statistics to the segmented area. "
Combining Ready View's accessibility with its many productivity tools such as autoprocessing, save state, one-click motion correction, and real time thresholding and segmentation, the software will not only help streamline image processing and analysis but help clinicians provide an effective diagnosis.
Related Links:
GE Healthcare
Latest Imaging IT News
- New Google Cloud Medical Imaging Suite Makes Imaging Healthcare Data More Accessible
- Global AI in Medical Diagnostics Market to Be Driven by Demand for Image Recognition in Radiology
- AI-Based Mammography Triage Software Helps Dramatically Improve Interpretation Process
- Artificial Intelligence (AI) Program Accurately Predicts Lung Cancer Risk from CT Images
- Image Management Platform Streamlines Treatment Plans
- AI-Based Technology for Ultrasound Image Analysis Receives FDA Approval
- AI Technology for Detecting Breast Cancer Receives CE Mark Approval
- Digital Pathology Software Improves Workflow Efficiency
- Patient-Centric Portal Facilitates Direct Imaging Access
- New Workstation Supports Customer-Driven Imaging Workflow